Aktienanalyse zu Corvus Pharmaceuticals Inc (CRVS)CRVSCorvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Corvus Pharmaceuticals Inc is a good buy right now due to its current price of $14.16, which is significantly lower than the analyst price target of $40 from Goldman Sachs. Additionally, the stock has shown a remarkable year-to-date change of +93.44%, indicating strong momentum. However, a key risk is the negative earnings per share (EPS) of -0.19 reported for Q2 2026, which reflects ongoing losses.

6 analysts cover CRVS: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 13.33.